Rankings
▼
Calendar
NAGE
Niagen Bioscience Inc
$423M
FY 2023 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$84M
+16.0% YoY
Gross Profit
$51M
60.8% margin
Operating Income
-$6M
-6.7% margin
Net Income
-$5M
-5.9% margin
EPS (Diluted)
$-0.07
Cash Flow
Operating Cash Flow
$7M
Free Cash Flow
$7M
Stock-Based Comp.
$5M
Balance Sheet
Total Assets
$55M
Total Liabilities
$27M
Stockholders' Equity
$28M
Cash & Equivalents
$27M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$84M
$72M
+16.0%
Gross Profit
$51M
$43M
+18.7%
Operating Income
-$6M
-$19M
+69.9%
Net Income
-$5M
-$17M
+70.1%
← Q4 2022
All Quarters
Q1 2023 →
NAGE FY 2023 Earnings — Niagen Bioscience Inc Revenue & Financial Results | Market Cap Arena